# Study of IBR733 Cell Injection in Acute Myeloid Leukemia

> **NCT06234904** · PHASE1 · UNKNOWN · sponsor: **Imbioray (Hangzhou) Biomedicine Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **BIOLOGICAL:** IBR733 Cell Injection

## Key facts

- **NCT ID:** NCT06234904
- **Lead sponsor:** Imbioray (Hangzhou) Biomedicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2024-02-01
- **Primary completion:** 2025-02-01
- **Final completion:** 2025-08-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06234904

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06234904, "Study of IBR733 Cell Injection in Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06234904. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*